User login
Key clinical point: RA patients who switched from oral to subcutaneous methotrexate reported an increased quality of life and reduced symptoms.
Major finding: The proportion of RA patients with symptom remission or low disease activity increased from 22.8% to 52.9% after changing from oral to subcutaneous delivery of methotrexate, combined with a dose increase in 34.8% of patients.
Study details: The data come from a prospective, observational study of 207 adults with RA who switched from oral to subcutaneous methotrexate; 6.7% were in remission and 15.5% had low disease activity at baseline.
Disclosures: The study was supported by NORDIC Pharma. Several study coauthors disclosed relationships with NORDIC Pharma, and several are employees of NORDIC Pharma.
Source: Senbel E et al. Patient Prefer Adherence. 2021 Apr 14. doi: 10.2147/PPA.S301010.
Key clinical point: RA patients who switched from oral to subcutaneous methotrexate reported an increased quality of life and reduced symptoms.
Major finding: The proportion of RA patients with symptom remission or low disease activity increased from 22.8% to 52.9% after changing from oral to subcutaneous delivery of methotrexate, combined with a dose increase in 34.8% of patients.
Study details: The data come from a prospective, observational study of 207 adults with RA who switched from oral to subcutaneous methotrexate; 6.7% were in remission and 15.5% had low disease activity at baseline.
Disclosures: The study was supported by NORDIC Pharma. Several study coauthors disclosed relationships with NORDIC Pharma, and several are employees of NORDIC Pharma.
Source: Senbel E et al. Patient Prefer Adherence. 2021 Apr 14. doi: 10.2147/PPA.S301010.
Key clinical point: RA patients who switched from oral to subcutaneous methotrexate reported an increased quality of life and reduced symptoms.
Major finding: The proportion of RA patients with symptom remission or low disease activity increased from 22.8% to 52.9% after changing from oral to subcutaneous delivery of methotrexate, combined with a dose increase in 34.8% of patients.
Study details: The data come from a prospective, observational study of 207 adults with RA who switched from oral to subcutaneous methotrexate; 6.7% were in remission and 15.5% had low disease activity at baseline.
Disclosures: The study was supported by NORDIC Pharma. Several study coauthors disclosed relationships with NORDIC Pharma, and several are employees of NORDIC Pharma.
Source: Senbel E et al. Patient Prefer Adherence. 2021 Apr 14. doi: 10.2147/PPA.S301010.